Posted On: AUG-2023 | Categories : Healthcare
The coronary stent is an essential part of the medical device sector. These stents are used to treat coronary artery disease. Over the past few years, coronary artery disease (CAD) has increased in middle-income or low-income countries due to lifestyle-related changes.
The rising frequency of coronary artery diseases (CADs) is stimulating the demand for coronary stents. Per the Centers for Disease Control & Prevention, heart disorders are the prevalent cause of death in the US. Heart disease caused nearly 695,000 fatalities in 2021. Coronary heart disease is the most prevalent type of heart disease that caused nearly 375,476 fatalities in 2021.
Per the American Heart Association, approximately 17.6 million people suffer from ischemic heart disease, which affects nearly 450,000 people in the United States annually and is the most prevalent heart disease.
The aging global population and improvements in stent technology and materials are also accelerating the demand for coronary stents. The senior population (65 years of age and older) is more susceptible to many chronic diseases, such as cardiovascular diseases (CVDs), which must be treated surgically since they can cause plaque accumulation in the arteries. Per the World Health Organization, aged population above the age of 60 will expand from 1 billion in 2020 to 1.4 billion by the year 2030. Between 2020- 2050, the number of people 80 or older will reach 426 million.
Besides PCI, Coronary angioplasty/stenting and coronary artery bypass surgery (CABS) are minimally invasive treatments. These methods are becoming more popular due to their advantages, which include shorter hospital stays, less scarring, less pain, minor surgical trauma, and an earlier return to normal activity. In the United States, more than 2 million stents are inserted annually, and nearly 1.2 Mn of them are coronary stents. Percutaneous coronary procedures (PCIs) involve the implantation of more than 600000 coronary stents each year in the US.
Percutaneous coronary intervention (PCI) procedures decreased 10% during the pandemic, from 100,000 in 2019–20 to 90,708 in 2020–21. Nearly 67% of cases with heart disease in 2020–21 involved intravascular imaging.
Side stem left PCI to support the best stent deployment, which ensures less immediate and long-term problems and enhances outcomes. This is a rise from 57% in the prior year.
The proportion of patients who had PCI within 72 hours after admission rose from roughly 55% to over 80% during the initial rise before tumbling down to around 60%.
The drug-eluting stents make up the majority of the share of 66.5%. Per the International Diabetes Federation (IDF), Diabetes affects 537 million individuals (20-79 years old) globally. By 2030, this figure will reach nearly 643 million, and by 2045, it will be 783 million. In 2021, diabetes caused nearly 6.7 million fatalities. Thus, with the rising rate of diabetes and cardiovascular disease, the demand for drug-eluting stents will expand. Companies like XIENCE Skypoint, Resolute Onyx from Medtronic, Synergy from Boston Scientific, and Abbott Laboratories are developing new technologically sophisticated DES.
After DES, bioresorbable scaffolds (BRS) are the most recent technology. In 2016, Abbott introduced the first vascular scaffold made of biodegradable material called Absorb.
The hospital is the largest end-user as they conduct a large number of surgeries like angioplasty because of their advanced facilities. Per the American College of Cardiology, more than 1.2 million angioplasties are carried out annually in the United States. The cost of stents ranges from USD 12,000-13,000. Drug-eluting stents are used in all hospital settings to maintain a proper level of care among patients.
North America is the largest region, with 32.33% of the revenue share. A coronary stent is common in North America due to a sedentary lifestyle that causes obesity and other cardiovascular disorders such as stroke, heart attack, and ischaemic heart disease (IHD). Coronary heart disease (CHD) (42.56%), followed by stroke (17.36%), other CVD (15.44%), high blood pressure (12.54%), heart failure (9.26%), and disorders of the arteries (2.84%), was the major cause of deaths attributed to CVD in the United States in 2020.
The market has also grown due to technological developments in coronary stent technologies, such as biodegradable materials and drug-eluting stents. The presence of established players like Abbott & Boston and Medtronic is driving the growth of the market in the area.
The Asia-Pacific region market for coronary stents will grow rapidly as China and India have high rates of cardiovascular disease. The National Center for Cardiovascular Diseases estimated that there were 330 million cardiovascular patients in China in 2020. In China, the annual number of operations for coronary heart disease climbed from 230,000 in 2009 to over 1 million in 2019. The coronary stent market will expand in Asia Pacific due to the aging population and the introduction of new products.
In the UK, about 100,000 stents are implanted annually. However, 1 in 20 stent procedures are done to address heart failure. In the UK, coronary artery disease is the most prominent cause of death, which accounts for more than 64,000 fatalities per year. Nearly 2.3 million people in the UK struggle with CAD. The UK spent $345.68 billion on healthcare in 2022, a 7.4% increase over the previous year. Following the effects of inflation on the general economy, the real rise in total current healthcare spending in the UK increased from 10.0% in 2021 to 7.1% in 2022. In the UK, healthcare expenditures in 2022 accounted for nearly 12% of GDP. In comparing the different UK nations, Northern Ireland experienced the highest decline in PCI procedures (19.7%), followed by England (10.3%) and Wales (1.2%). In England, almost 371,000 heart procedures and operations were carried out in 2020, a 22% decrease from 2019 (473,000 surgery).
Market players are constantly working to bring new innovations and technology in the field of coronary stents. Following are companies that are working in the field of coronary stents:
Boston Scientific was the market leader for coronary stents. Its success is due to its dominance in the drug-eluting stents (DES) industry, where it holds the largest market share.
The company is now offering the SYNERGYTM and REBELTM BMS product lines. The first and only DES with an abluminal bioabsorbable polymer covering that has received FDA approval and is offered on the U.S. coronary stent market is SYNERGYTM. The platinum chromium alloy used in REBELTM was developed to cut down on radiation exposure, process times, and gadget usage.
It is the 2nd leading competitor in the market for drug-eluting stents & bare metal stents market. Medtronic has improved its market position in interventional cardiology through strategic acquisitions and aggressive bundling.
Its product line includes Resolute Onyx, Resolute Integrity DES, & Integrity. The DES devices made by Medtronic use zotarolimus rather than the medication everolimus, like those made by Boston Scientific and Abbott.
It is the 3rd leading coronary stent company. Its product line includes XIENCE & Multi-Link Vision. Multi-Link VisionTM has been the dominant BMS in the United States. The XIENCE DES provides patients with unmatched outcomes both during and long after percutaneous coronary procedures (PCI). The XIENCE Stent has been implanted in more than 20 million patients and has been the subject of more than 120 clinical trials.
In order to treat PAD, Cook Medical was a pioneer in the creation of drug-eluting stent (DES) technology, which combines a medical device and medication. The Zilver PTX from Cook is the first DES used to treat PAD in the superficial femoral artery (SFA).
In January 2022, The FDA classified Cook Medical's novel drug-eluting stent (DES) for below-the-knee (BTK) use as a Breakthrough Device. Patients with chronic limb threatening ischemia can be treated with the device.
B Braun is one of the top producers and suppliers of efficient solutions for the global leader in healthcare. Coroflex ISAR NEO is newest generation of drug eluting stents. It offers continuous and regulated drug administration because of the well-proven polymer free matrix coating. The Coroflex ISAR NEO catheter features the most advanced drug-eluting technology for use in complex lesions when combined with the catheter platform of the most recent generation from B. Braun.
Biotronik SE & Co. creates, produces, and sells cardiovascular and endovascular solutions. Its electrophysiology devices product line includes heart catheters, which are used to identify and treat cardiac arrhythmias. Vascular intervention products, such as stent systems, balloon catheters, and guide wires, are also included in its product line.
For treating coronary artery stenosis, the Orsiro Hybrid Drug-Eluting Stent offers the ideal blend of simple deliverability and a hybrid coating. This innovative idea creates a new class of drug-eluting stents that can improve patient outcomes even for lengthy lesions.
Orsiro uses the PRO Kinetic Energy Platform, which provides bending flexibility without compromising the structure strength or the resilience to fatigue.
In order to treat acute myocardial infarction or coronary artery disease, Stentys SA has focused on developing a new generation of stents. The self-expanding, bare-metal STENTYS Stent, the company's flagship product, is recommended for the treatment of acute coronary syndrome.
The Stentys Self-Apposing stent was made to adapt to challenging targets and enhance strut apposition to the vessel wall.
Within 20 years, MicroPort has become a world leader in the Percutaneous Coronary Intervention (PCI) industry. Its unique Firehawk targeted eluting stent system has established itself as a market leader, with strong clinical evidence supporting its safety and efficacy.
As the first & only Target Eluting Stent, Firehawk has more than 600 grooves on the strut surface and uses a target release mechanism that reduces the dosage required by a third compared to traditional stents.
A leader in developing and marketing cutting-edge, life-improving medical technology, C. R. Bard, Inc. specializes in the product areas of vascular, urology, oncology, and surgical specialty.
E-LUMINEXX Vascular Stent, Covera Vascular Covered Stent, LifeStent Vascular Stent Graft, and Fluency Plus Endovascular Stent Graft are the product lines offered by C.R. Bard.
The LIFESTENT Vascular Stent device is intended to provide a self-expanding stent to the peripheral vascular via a sheathed delivery device.
The CoveraTM Vascular Covered Stent is used to treat stenoses at the venous anastomosis of synthetic AV grafts and AV fistulas in hemodialysis patients.
Terumo Medical Corporation is one of the world's top producers of medical equipment and supplies. Ultimaster Nagomi, Ultimaster, & Ultimaster Tansei are the three product lines offered by Terumo Medical Corporation.
The company Biosensors International Group Ltd. manufactures blood pressure transducers, critical care catheter systems, and drug-eluting stents intended to expand arteries that are getting too narrow.
BioMatrix NeoFlex, Powerline, BioFreedom, BioMatrix Alpha, BioFreedom Ultra, BMX-J, BioPath, BioStream, Juno, S-Stent, Rise NC, and Quadrature Link are the different product lines offered by Biosensors International Group Ltd.
Meril Life Sciences Pvt Limited
Meril Life Sciences Pvt Ltd. provides a wide range of cardiovascular devices to meet the most recent industry requirements. Evermine50, BioMime Lineage, Proficient, Metaphor, BioMime Branch, BioMime Morph, and NexGen are the different types of coronary stents offered by Meril Life Sciences Pvt Ltd.
Evermine50 is a 50-m ultra-thin strut that encourages rapid vascular repair. Everolimus is a medication with a demonstrated track record for clinical safety and long-term efficacy.
The tried-and-true BioMime stent, BioMime LineageT, features an innovative hybrid form with closed and open cells that enables morphology-mediated expansion.
In order to eliminate multiple stent installations and decrease the risk of fracture and restenosis, Biomime MorphT tapers in accordance with vascular anatomy.
Proficient is an ultra-thin 65-m strut thickness sirolimus-eluting coronary stents system that enables faster healing due to biodegradable polymer.
BioMime has ultra-thin (65 m) struts with closed cells on both ends of the stent and open cells in the center; the next generation (SES) offers a novel hybrid design that enables morphology-mediated expansion for sufficient conformability and fewer edge dissections.
BioMime Branch is a bifurcation stent system that helps in lesions of the bifurcations.
NexGen is a bare metal stent with a strut thickness of only 65 m. Morphology Mediated Expansion is made possible by the hybrid stent design, which has closed cells on both ends and open cells in the middle. This results in appropriate conformability and fewer edge dissections.
Elixir Medical develops stents with drug-eluting capabilities that optimize targeted medication delivery and offer a secure and efficient means of treating cardiovascular disease.
The DynamXTM Drug Eluting Coronary Bioadaptor System represents a substantial advancement in the management of coronary artery disease. In contrast to drug eluting stents, DynamX is the most important development in implant design.
The low-profile DESyne X2 Novolimus Eluting Coronary Stent System has great deliverability and maximum flexibility. One of the thinnest coated struts is made possible by the ultra-thin design of its stent and polymer coating.
With the help of Endologoics, Stent aortic problems can be treated with minimally invasive procedures.
Patients with abdominal aortic aneurysms with vascular morphology suited for endovascular repair are treated with the Endologix Ovation Abdominal Stent Graft System.
Relisys Medical Devices develops Stents & catheters to treat structural heart disease, peripheral vascular disease, and cardiovascular disease. The products include drug-eluting stent systems for sirolimus and paclitaxel (Release-R and Release-T) and bare metal stent systems (Cobal-C, Cobal-CE, and Legend-V).
Deep venous stenting treatments are available from Vesper Medical. Stents that revive venous flow are part of the startup's DUO Venous Stent System offering. The stents can be adjusted for therapy and provide pain relief for conditions like CVI. Medical professionals can access veins ranging from the femoral vein to the inferior vena cava (IVC) by utilizing cranial strength and caudal flexibility.
French medical technology startup Open Stent Solution is creating the first open stent heart valve. Stent Solution has received funding to develop its ribbon-shaped transcatheter stented mitral valve.
Their invention is the first stent heart valve that can implant large mitral valves through small delivery systems.
Endospan is a leader in the endovascular repair of aortic arch illness, including aneurysms and dissections. The NEXUS Aortic Arch Stent Graft System from Endospan is the first endovascular off-the-shelf system to treat a group of patients with dilative lesions in or near the aortic arch, an extremely undertreated condition.
Svelte Medical Systems is a manufacturer of the integrated delivery system for drug-eluting coronary stents on a wire used to treat coronary artery disease. The company's device combines proprietary balloon technology with specialized guide wire tip technology to improve direct stenting and navigate coronary arteries like a guide wire, typically obviating the need for additional guide wires and balloons and allowing patients to experience better clinical outcomes, increased comfort, and shorter procedure times and lower costs.